X0306 4 2020-04-02 1 0001481512 Ra Pharmaceuticals, Inc. RARX 0001328625 Mathers Edward T 1954 GREENSPRING DRIVE, SUITE 600 TIMONIUM MD 21093 1 0 0 0 Stock Option (Right to Buy) 22.37 2020-04-02 4 D 0 15000 D 2027-06-20 Common Stock 15000 0 D Stock Option (Right to Buy) 9.90 2020-04-02 4 D 0 15000 D 2028-06-28 Common Stock 15000 0 D Stock Option (Right to Buy) 19.88 2020-04-02 4 D 0 15000 D 2029-06-11 Common Stock 15000 0 D Pursuant to the Agreement and Plan of Merger, dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. /s/ Sasha Keough, attorney-in-fact 2020-04-03